Roche and AbbVie line up for quick approval for cancer drug venetoclax

Partners Roche ($RHHBY) and AbbVie ($ABBV) are speeding toward FDA approval with a cancer treatment tabbed as a potential blockbuster, picking up a priority review for a blood cancer therapy.

The drug, venetoclax, is up for a shortened 6-month FDA review in chronic lymphocytic leukemia after receiving the FDA's breakthrough therapy designation.

In Phase II trials, the treatment met its main goal of beating back cancer growth in CLL. Venetoclax, formerly ABT-199, is designed to block the protein B-cell lymphoma-2, which can help cancer cells survive in the blood. The drug's first target is patients who have CLL with a 17p deletion, a tough-to-treat variant that accounts for up to 10% of all CLL cases and as many as half of all relapsed or refractory instances of the cancer, according to AbbVie.

AbbVie and Roche are taking a broad approach to blood cancer with venetoclax, running late-stage studies in other forms of CLL and mid-stage trials testing the drug against non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, acute myeloid leukemia and multiple myeloma.

The drug's future is particularly vital to AbbVie, which paid $21 billion for Pharmacyclics last year to get a 50% share of the CLL drug Imbruvica. AbbVie believes Imbruvica can bring in billions a year with the help of a widened label, and pairing it with venetoclax could create a best-in-class combination, according to the company.

- read the statement

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.